论文部分内容阅读
目的:探讨肺纤方干预肺间质纤维化炎性反应及纤溶抑制的作用。方法:将大鼠分为假手术组、模型组、泼尼松组、氯沙坦组、肺纤方提取物高、中、低剂量组(2.4,1.2,0.6 g·kg-1)7组,采用气管插管灌注博莱霉素3 mg·kg-1进行大鼠肺间质纤维化造模。造模第2天予药物灌胃干预。于第14,28天分两批进行动物处理,HE染色观察肺泡炎程度,Masson染色观察肺纤维化程度。RT-PCR检测血管细胞黏附分子(VCAM-1),纤溶酶原激活物抑制因子(PAI-1)基因表达。结果:肺纤方中剂量组能够显著抑制肺泡炎、肺纤维化程度,降低VCAM-1,PAI-1mRNA表达。结论:肺纤方通过抑制VCAM-1,PAI-1基因表达,减轻炎性反应、改善纤溶抑制而发挥抗纤维化作用。
Objective: To investigate the effects of Fei Xian Fang on pulmonary fibrosis inflammatory reaction and fibrinolysis inhibition. Methods: The rats were divided into 7 groups (sham operation group, model group, prednisone group, losartan group, high, medium and low doses of Pulmonary fibula extract) (2.4, 1.2 and 0.6 g · kg -1) , Intratracheal intratracheal instillation of bleomycin 3 mg · kg-1 rat pulmonary interstitial fibrosis modeling. The second day of modeling to drug gavage intervention. Animals were treated in two batches on the 14th and 28th days. The degree of alveolitis was observed by HE staining and the degree of pulmonary fibrosis was observed by Masson staining. The expression of vascular cell adhesion molecule (VCAM-1) and plasminogen activator inhibitor (PAI-1) gene were detected by RT-PCR. Results: Pulmonary fibrosis mid-dose group can significantly inhibit alveolitis, pulmonary fibrosis, reduce the expression of VCAM-1, PAI-1mRNA. Conclusion: Feixian Prescription can play an anti-fibrosis effect by inhibiting the expression of VCAM-1 and PAI-1 gene, reducing inflammatory reaction and improving fibrinolytic inhibition.